SGLT2 inhibition could lower stroke risk in those with diabetes plus atrial fibrillation

SGLT2 inhibition was associated with reduced 5-year risk for stroke among patients with concomitant atrial fibrillation and diabetes, according to a study in the Journal of the American Heart Association. “From the animal studies, SGLT2 inhibitors could decrease oxidative stress in cardiomyocytes, reverse myocardial remodeling and reduce electronic alterations. These pleiotropic effects of

Related Keywords

Taiwan ,National Taiwan University ,T Ai Pei ,United States ,National Taiwan University Hospital ,American ,Boehringer Ingelheim Eli Lilly ,Sheng Nan Chang ,National Taiwan University Hospital In Yun Lin ,Journal Of The American Heart Association ,Astrazeneca ,American Heart ,Nan Chang ,Eli Lilly ,